Literature DB >> 24152832

Immunostimulants and prevention of recurrent respiratory tract infections.

S Esposito1, A Musio.   

Abstract

Recurrent respiratory tract infections (RRTIs) are very common in children and a major challenge for pediatricians. They affect the children's quality of life, cause absences from school and lost parental working days, and repeated medical examinations, hospital admissions as well as antibiotic therapies lead to high costs for society. Given their prevalence and clinical importance, various prevention strategies have been developed. One of the most widely used is the administration of immunostimulants: i.e. molecules of bacterial or synthetic origin that interact with immunological mechanisms in vitro and in vivo. A number of studies have investigated their effects on cellular and innate immunity, and their clinical efficacy, but there is no consensus as to their real usefulness. The main aim of this review is to analyse the available data concerning the activity and efficacy of immunostimulants in preventing pediatric RRTIs. The majority of studies have shown that the number of infections decreases after immunostimulant treatment, but they are affected by various methodological weaknesses. Further studies are urgently needed to confirm whether, when and which immunostimulants should be used.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24152832

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  8 in total

Review 1.  Role of biofilm in children with recurrent upper respiratory tract infections.

Authors:  E Nazzari; S Torretta; L Pignataro; P Marchisio; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-16       Impact factor: 3.267

2.  Dynamic monitoring and a clinical correlation analysis of the serum vitamin A, D, and E levels in children with recurrent respiratory tract infections.

Authors:  Mei Sun; Zhixin Yan; Rongrong Sun; Wenqiu Tian; Wenxia Yi; Jing Zhang
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

3.  Clinical efficacy and tolerability of an immune-stimulant(*) constituted by inactivated bacterial bodies in the prophylaxis of infectious episodes of airways: a double blind, placebo-controlled, randomized, multicentre study.

Authors:  Stefano Carlone; Michele Minenna; Paride Morlino; Luigi Mosca; Franco Pasqua; Riccardo Pela; Pietro Schino; Alberto Tubaldi; Emmanuele Tupputi; Fernando De Benedetto
Journal:  Multidiscip Respir Med       Date:  2014-11-19

4.  Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study.

Authors:  Susanna Esposito; Sonia Bianchini; Ilaria Polinori; Nicola Principi
Journal:  Int J Environ Res Public Health       Date:  2019-03-25       Impact factor: 3.390

5.  A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections.

Authors:  Susanna Esposito; Sonia Bianchini; Samantha Bosis; Claudia Tagliabue; Ilaria Coro; Alberto Argentiero; Nicola Principi
Journal:  J Transl Med       Date:  2019-08-23       Impact factor: 5.531

6.  Association of recurrent upper respiratory tract infections with low production of oxygen intermediates in children.

Authors:  Natália Vieira Inácio Calapodopulos; Mônica Miguel Sawan-Mendonça; Marcos Vinicius da Silva; Carlo Jose Freire Oliveira; Virgínia Resende Weffort; Denise Bertululucci Rocha Rodrigues; Virmondes Rodrigues
Journal:  J Pediatr (Rio J)       Date:  2021-11-26       Impact factor: 2.990

7.  Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia.

Authors:  Susanna Esposito; Micaela Garziano; Veronica Rainone; Daria Trabattoni; Mara Biasin; Laura Senatore; Paola Marchisio; Marta Rossi; Nicola Principi; Mario Clerici
Journal:  J Transl Med       Date:  2015-09-03       Impact factor: 5.531

8.  The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3).

Authors:  Francesca Caccuri; Antonella Bugatti; Silvia Corbellini; Sara Roversi; Alberto Zani; Pietro Mazzuca; Stefania Marsico; Arnaldo Caruso; Cinzia Giagulli
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.